The performance of the p53 +/- transgenic (knockout) mouse model was evaluated through review of the data from 31 short-term carcinogenicity studies with 21 compounds tested as part of the International Life Sciences Institute's (ILSI) Alternatives to Carcinogenicity Testing (ACT) project, together with data from other studies which used comparable protocols. As expected based on the hypothesis for the model, a significant number (12/16 or 75%) of the genotoxic human and/or rodent carcinogens tested were positive and the positive control, p-cresidine, gave reproducible responses across laboratories (18/19 studies positive in bladder). An immunosuppressive human carcinogen, cyclosporin A, was positive for lymphomas but produced a similar response in wild type mice. Two hormones that are human tumorigens, diethylstilbestrol and 17β-estradiol, gave positive and equivocal results, respectively, in the pituitary with p53-defi cient mice showing a greater incidence of proliferative lesions than wild type. None of the 22 nongenotoxic rodent carcinogens that have been tested produced a positive response but 2 compounds in this category, chloroform and diethylhexylphthalate, were judged equivocal based on effects in liver and kidney respectively. Four genotoxic noncarcinogens and 6 nongenotoxic, noncarcinogens were also negative. In total (excluding compounds with equivocal results), 42 of 48 compounds or 88% gave results that were concordant with expectations. The technical lessons learned from the ILSI ACT-sponsored testing in the p53+/- model are discussed.
Aardema MJ, Isfort RJ, Thompson ED, LeBoeuf RA (1996). The low pH Syrian hamster embryo (SHE) cell transformation assay: A revitalized role in carcinogen prediction. Mutat Res356(1): 5—9.
2.
Allen J., personal communication, September, 2000.
3.
Balachandra Dass S., Bucci TJ, Hefl ich RH, Casciano DA (1999). Evaluation of the transgenic p53+/- mouse for detecting genotoxic liver carcinogens in a short-term bioassay. Cancer Lett143: 81—85.
4.
Blanchard KT, Barthel C., French JE, Holden HE, Moretz R., Pack FD, Tennant RW, Stoll RE (1999). Transponder-induced sarcoma in the heterozygous p53+/- mouse. Toxicol Pathol27(5): 519—527.
5.
Caldwell J, this volume.
6.
Carmichael NG, Debruyne ELM, Bigot-Lasserre D. (2000). The p53 heterozygous knockout mouse as a model for chemical carcinogenesis in vascular tissue. Environ Health Perspect108(1): 61—65.
7.
Contrera JF, DeGeorge JJ (1998). In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals. Environ Health Perspect106(Suppl 1): 71—80.
8.
Donehower LA (1996). The p53-defi cient mouse: A model for basic and applied cancer studies. Semin Cancer Biol7: 269—278.
9.
Donehower LA , Godley LA, Aldaz CM, Pyle R., Shi Y-P., Pinkel D., Gray J., Bradley A., Medina D., Varmus HE (1995). The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model . Prog Clin Biol Res395: 1—11.
10.
Donehower LA , Harvey M., Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. (1992). Mice defi cient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature356: 215—221.
11.
Donehower LA , Harvey M., Vogel H., McArthur MJ, Montgomery CA Jr, Park SH, Thompson T., Ford RJ, Bradley A. (1995). Effects of genetic background on tumorigenesisin p53-defi cient mice. Mol Carcinogen14: 16—22.
12.
Donehower LA, this volume
13.
Dunnick JK, Hardisty JF, Herbert RA, Seely JC, Furedi-Machacek EM, Foley JF, Lacks GD, Stasiewicz S., French JE (1997). Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild-type allele in heterozygous p53-defi cient (+/-) mice . Toxicol Pathol25: 533—540.
14.
Eastin WC, Haseman JK, Mahler JF, Bucher JR (1998). The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens . Toxicol Pathol26(4): 461—473.
15.
French, JE, this volume
16.
French JE, personal communication (glycidol, methylphenidate chloroprene), October, 2000.
17.
Finch GL, March TH, Hahn FF, Barr EB, Belnisky SA, Hoover MD, Lechner JF, Nikula KJ, Hobbs CH (1998) Carcinogenic responses of transgenic heterozygous p53 knockoutmice to inhaled 239PuO2 or metallic beryllium. Toxicol Pathol26(4): 484—491.
18.
Furst SM, Blanchard KT, Lilly PD, Holden HE, Stoltz JH, Barthel C., Stoll RE (1999). Six month oral gavage and diet carcinogenic study with phenolphthalein in the heterozygous p53+/- mouse. Toxicol Sci48(1-S): A1202.
19.
Gulezian D. , Jacobson-Kram D., McCullough CB, Olson HM, Recio L., Robinson DE, Storer RD, Tennant RW, Ward J., Neumann D. (2000). Use of transgenic animals for carcinogenicity testing: Considerations and implications for risk assessment . Toxicol Pathol28(3): 482—499.
20.
Harvey M., McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A., Donehower LA (1993). Spontaneous and carcinogen-induced tumorigenesis in p53-defi cient mice. Nature Gen5: 225—229.
21.
Harvey M., Vogel H., Morris D., Bradley A., Bernstein A., Donehower LA (1995). A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-defi cient mice. Nat Genet9: 305—311.
22.
International Conference on Harmonisation (1998). Guidance on testing for carcinogenicity of pharmaceuticals. Fed Reg63: 8983—8986.
23.
Jacobsen-Kram D., personal communication, August, 1998.
24.
Joseph Jerry D, Butel JS, Donehower LA, Paulson EJ, Cochran C., Wiseman, RW, and Medina, D. (1994). Infrequent p53 mutations in 7,12-dimethyl[a]benzanthracene-induced mammary tumors in BALB/c and p53 hemizygous mice. Mol Carcinogen9: 175—183.
25.
Jiang W., Ananthaswamy HN, Muler HK, Kripke, ML (1999). p53 protects against skin cancer inductionby UV-B radiation. Oncogene18: 4247— 4253.
26.
Kemp CJ (1995). Hepatocarcinogenesis in p53-deficient mice. Mol Carcinogen12:132—136.
27.
Kemp CJ, Donehower LA, Bradley A., Balmain A. (1993). Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell74:813—822.
28.
Kemp CJ, WheldonT, Balmain A (1994). p53-defi cient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet8: 66—69.
29.
Mahler JF, Flagler ND, Malarkey DE, Mann PC, Haseman JK, Eastin W. (1998). Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice. Toxicol Pathol26: 501—511.
30.
Mirsalis JC , Hursey JA, Johnson A.Fairchild DG, Kanazawa N. W inegar, RA (2001). Evaluation of tumors and mutations in p53+/-, CII double transgenic mice treated with various test agents. Toxicol60(1): A969.
31.
Mitsumori K. , Onodera H., Shimo T., Yasuhara K., Takagi H., Koujitani T., Hirose M., Maruyama C.Wakana S. (2000). Rapid induction of uterine tumors with p53 point mutations in heterozygous p53-deficient CBA mice given a single intraperitoneal administration of N-ethyl-N-nitrosourea . Carcinogenesis21(5): 1039—1042.
32.
Mitsumori K. , Yasuhara K., Onondera H., Koujitani T., Takagi H., Hirose M., Usui T., Tamaoki N., Nomura T. (2000). ILSI Health and Environmental SciencesWorkshop on the Evaluation of Alternative Methods for Carcinogenicity Testing: Poster #19. Leesburg, VA.
33.
Morimura K. , Salim EI, Yamamoto S., Wanibuchi H., Fukushima S. (1999). Dose-dependent induction of aberrant crypt foci in the colons but no neoplastic lesions in the livers of heterozygous p53-deficient mice treated with low dose 2-amino-3-methylimidazo[4, 5- f ]quinoline. Cancer Lett138: 81—85.
34.
Ozaki K., SukataT., Yamamoto S., Uwagawa S., SekiT., Kawaski H., Yoshitake A., Wanibuchi H., Koide A., Mori Y., Fukushima S. (1998). High susceptibility of p53(+/-) knockout mice in n-butyl-N-(4-hydroxybutyl ) nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res58(17): 3806—3811.
35.
Park, CB, Kim, DJ, Uehara, N., Takasuka, N., Hiroyasu, B-T., and Tsuda, H. (1999). Heterozygous p53-defi cient mice are not susceptible to 2-amino-3,8-dimethylimidazo[4, 5- f ]quinoxaline (mIQx) carcinogenicity . Cancer Lett139:177—182.
36.
Popp J, this volume.
37.
Recio L., personal communication, October, 2000.
38.
Robinson D. (1998). The International Life Science Institute's role in the evaluation of alternative methodologies for the assessment of carcinogenic risk. Toxicol Pathol26(4): 474—475.
39.
Sagartz JE, Curtiss SW, Bunch RT, Davila JC, Morris DL, Alden CL (1998). Phenobarbital does notpromote hepatictumorigenesis in a twenty-six-week bioassay in p53 heterozygous mice. Toxicol Pathol26: 492—500.
40.
Spalding JW , French JE, Stasiewicz S., Furedi-Machacek M., Conner F., Tice RR, Tenant RW (2000). Responses of transgenic mouse lines p53+/- and Tg.AC to agents tested in conventional bioassays. Toxicol Sci53: 213—223.
41.
Stoll RE, Holden HE, Barthel CH, Blanchard KT (1999). Oxymetholone: III. Evaluation in the p53+/-transgenic mouse model. ToxicolPathol27(5): 513—518.
42.
Storer RD (2000). Current status and use of short/medium term models for carcinogenicity testing of pharmaceuticals—Scientifi c perspective . Toxicol Lett112-113: 557—566.
43.
Tennant RW, French JE, SpaldingJW (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ Hlth Perspect103, 942—950.
44.
Tennant RW, Spalding J., French JE (1996). Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mut Res365: 119—127.
45.
Tennant, RW (1998). Evaluation and validation issues in the development of transgenic mouse carcinogenicity bioassays. Environ Health Perspect106 (Suppl 2): 473—476.
46.
Torti VR, Cobb AJ, Everitt JI, Marshall MW, Wong BA, Boorman GAButterworth BE (2001). Bromodichloromethane inhalation in p53+/- mice: Assessment of toxic and tumorigenic responses. Toxicologist60 (1): A1326.
47.
Venkatachalam S., Shi Y-P., Jones SN, Vogel H., Bradley A., Pinkel D., Donehower LA (1998). Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 gene dosage can promote cancer formation. EMBO J17(16): 4657—4667.
